Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

4.00USD
22 Jun 2018
Change (% chg)

$-0.05 (-1.23%)
Prev Close
$4.05
Open
$4.05
Day's High
$4.05
Day's Low
$3.92
Volume
69,754
Avg. Vol
64,448
52-wk High
$5.75
52-wk Low
$1.58

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2018 Mar '18 0.34 -0.228
FY 2017 Dec '17 0.74 0.480
Sep '17 1.49 -0.281
Jun '17 2.66 -0.288
Mar '17 3.11 -0.343
FY 2016 Dec '16 6.43 -0.214
Sep '16 3.37 -0.252
Jun '16 4.53 -0.245
Mar '16 3.03 -0.242
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Jun-18 4 1.14 2.30 0.40 5.56
Quarter Ending Sep-18 4 2.84 7.90 0.40 18.58
Year Ending Dec-18 5 6.44 10.70 1.60 31.22
Year Ending Dec-19 5 21.81 30.20 9.10 77.54
Earnings (per share)
Quarter Ending Jun-18 5 -0.21 -0.20 -0.23 -0.24
Quarter Ending Sep-18 5 -0.21 -0.12 -0.24 -0.05
Year Ending Dec-18 5 -0.89 -0.85 -0.99 -0.82
Year Ending Dec-19 5 -0.79 -0.55 -1.00 -0.09
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 248.83 34.14
P/E High - Last 5 Yrs. -- 293.42 47.76
P/E Low - Last 5 Yrs. -- 100.49 25.04
Beta 2.41 0.74 0.78
Price to Sales (TTM) 39.26 246.52 8.17
Price to Book (MRQ) -- 23.99 4.30
Price to Tangible Book (MRQ) -- 30.50 6.00
Price to Cash Flow (TTM) -- 145.85 22.70
% Owned Institutions 27.47 11.95 2.44

Dividends

  Company industry sector
Dividend Yield -- 0.33 1.70
Dividend Yield - 5 Year Avg -- 0.20 1.43
Dividend 5 Year Growth Rate -- 2.19 -6.26
Payout Ratio(TTM) -- 41.90 42.76

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago -88.97 27.24 5.16
Sales (TTM) vs TTM 1 Yr. Ago -70.02 139.74 13.40
Sales - 5 Yr. Growth Rate 27.27 31.45 7.89
EPS (MRQ) vs Qtr. 1 Yr. Ago 33.63 -84.38 39.68
EPS (TTM) vs TTM 1 Yr. Ago 70.01 -- --
EPS - 5 Yr. Growth Rate -- 49.40 8.05
Capital Spending - 5 Yr. Growth Rate 23.83 37.00 7.35

Financial Strength

  Company industry sector
Quick Ratio (MRQ) 4.00 1.67 2.55
Current Ratio (MRQ) 4.05 6.39 3.63
LT Debt to Equity (MRQ) -- 22.27 13.12
Total Debt to Equity (MRQ) -- 26.58 17.55
Interest Coverage (TTM) -2.90 -141.36 36.62

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -46.26 56.61 55.11
Gross Margin - 5 Yr. Avg. -- 55.12 52.97
EBITD Margin (TTM) -639.99 -- --
EBITD - 5 Yr. Avg -159.97 -170.99 15.68
Operating Margin (TTM) -667.01 -889.67 -0.25
Operating Margin - 5 Yr. Avg. -170.05 -184.49 10.87
Pre-Tax Margin (TTM) -922.74 -784.00 1.68
Pre-Tax Margin - 5 Yr. Avg. -221.62 -188.52 11.03
Net Profit Margin (TTM) -257.14 -777.70 -1.61
Net Profit Margin - 5 Yr. Avg. -178.66 -187.13 7.38
Effective Tax Rate (TTM) -- 15.50 29.97
Effective Tax Rate - 5 Yr. Avg. -- 19.39 24.15

Efficiency

  Company industry sector
Revenue/Employee (TTM) 127,537 22,135,587 727,159,976
Net Income/Employee (TTM) -327,951 -51,964 84,694,665
Receivable Turnover (TTM) 3.01 18.41 6.01
Inventory Turnover (TTM) 6.07 2.85 3.67
Asset Turnover (TTM) 0.07 0.48 0.87

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -17.43 -3.55 10.32
Return on Assets - 5 Yr. Avg. -28.68 -0.74 10.99
Return on Investment (TTM) -20.97 -5.25 13.10
Return on Investment - 5 Yr. Avg. -32.46 2.09 14.28
Return on Equity (TTM) -- -6.83 15.09
Return on Equity - 5 Yr. Avg. -96.91 -2.95 15.63
  1 Year 3 Year 5 Year
Sales % -53.94 15.29 27.27
EPS (TTM) % 61.02 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for AcelRx Pharmaceuticals Inc

Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 9.20%
# of Holders: 66
Total Shares Held: 4,721,183
3 Mo. Net Change: -9,733,557
# New Positions: 10
# Closed Positions: 13
# Increased Positions: 22
# Reduced Positions: 26
# Net Buyers: -4
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.